XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
AEG35156 is a second generation antisense which targets XIAP mRNA to lower XIAP levels and
the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and
chemotherapy. Advanced HCC is an attractive target for AEG35156 since XIAP is highly
expressed in HCC and may prevent cancer cells from undergoing apoptosis. Second generation
antisense molecules are known to accumulate in liver where AEG35156 may down regulate XIAP
protein expression in HCC cells thus promoting their apoptotic death.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Aegera Therapeutics
Collaborator:
Chinese University of Hong Kong
Treatments:
Niacinamide Sorafenib X-Linked Inhibitor of Apoptosis Protein